Supplementary Table1. Distribution of IL-10 -592A/C, -819T/C,-1082G/Agenotypes and allele frequency in recipients and donorsamong aGvHD patients and control subjects.
First author and year / Number of total recipients or donors / Grades ofcase-aGvHD / Incidence of case-aGVHD (%) / Control-aGvHD(n) / Case-aGvHD(n) / MAF / Donor type / Ethnicity / aGvHD prophylaxis-592 A/C in recipients with grade III-IV aGvHD
CC / CA / AA / CC / CA / AA / A
Tseng200911 / 692 / III-IV / 36.8 / 257 / 143 / 37 / 145 / 92 / 18 / 0.249 / IU+IS / NA / CsA+MTX
Lin 200512 / 953 / III-IV / 18.7 / 393 / 309 / 73 / 111 / 59 / 8 / 0.278 / IS / Mixed / CsA+MTX
Sivula200913 / 304 / III-IV / 9.5 / 172 / 90 / 13 / 14 / 10 / 5 / 0.223 / IS / NA / CsA+MTX
CsA+MMF
Lin 200314 / 570 / III-IV / 18.1 / 228 / 193 / 46 / 68 / 29 / 6 / 0.286 / IS / NA / CsA+MTX
-592 A/C in recipients with grade II-IV aGvHD
CC / CA+AA / CC / CA+AA / A
Xiao 201015 / 138 / II-IV / 43.5 / 5 / 73 / 17 / 43 / 0.623 / IU+IS / Asian / CsA+MTX
CsA+MMF
Xiao 201015 / 102 / II-IV / 23.5 / 10 / 68 / 7 / 17 / 0.637 / IS / Asian / CsA+MTX
CsA+MMF
Bertinetto 200616 / 77 / II-IV / 41.6 / 23 / 22 / 19 / 13 / 0.260 / IS / European / CsA+MTX
CsA+MMF
Azarpira200817 / 18 / II-IV / 50 / 1 / 8 / 2 / 7 / 0.417 / IS / NA / CsA+MTX
Socié200118 / 100 / II-IV / 40 / 10 / 51 / 12 / 28 / 0.39 / IS / NA / CsA+MTX
-592 A/C in donors with grade III-IV aGvHD
CC / CA / AA / CC / CA / AA / A
Sivula 200913 / 309 / III-IV / 9.3 / 175 / 93 / 12 / 14 / 10 / 5 / 0.221 / IS / NA / CsA+MTX
CsA+MMF
Tseng 200911 / 901 / III-IV / 37.2 / 328 / 213 / 25 / 177 / 137 / 21 / 0.245 / IU+IS / NA / CsA+MTX
Lin 200512 / 953 / III-IV / 18.7 / 389 / 308 / 78 / 103 / 63 / 12 / 0.289 / IS / Mixed / CsA+MTX
Lin 200314 / 570 / III-IV / 18.2 / 238 / 186 / 42 / 60 / 38 / 6 / 0.280 / IS / NA / CsA+MTX
-592 A/C in donors with grade II-IV aGvHD
CC / CA+AA / CC / CA+AA / A
Xiao 201015 / 138 / II-IV / 43.5 / 11 / 67 / 16 / 44 / 0.609 / IU+IS / Asian / CsA+MTX
CsA+MMF
Xiao 201015 / 102 / II-IV / 23.5 / 8 / 80 / 7 / 17 / 0.661 / IS / Asian / CsA+MTX
CsA+MMF
Bertinetto 200616 / 77 / II-IV / 41.6 / 29 / 16 / 19 / 13 / 0.214 / IS / European / CsA+MTX
CsA+MMF
Azarpira 200817 / 18 / II-IV / 38.9 / 2 / 9 / 1 / 6 / 0.528 / IS / NA / CsA+MTX
Socié200118 / 100 / II-IV / 42 / 13 / 45 / 9 / 33 / 0.34 / IS / NA / CsA+MTX
-819T/C in recipients with grade II-IV aGvHD
TT+TC / CC / TT+TC / CC / T
Xiao 201015 / 138 / II-IV / 43.5 / 73 / 5 / 41 / 19 / 0.384 / IU+IS / Asian / CsA+MTX
CsA+MMF
Xiao 201015 / 102 / II-IV / 23.5 / 68 / 10 / 16 / 8 / 0.397 / IS / Asian / CsA+MTX
CsA+MMF CsA+MMF
Bertinetto 200616 / 77 / II-IV / 41.6 / 22 / 23 / 13 / 19 / 0.26 / IS / European / CsA+MTX
CsA+MMF
Azarpira 200817 / 18 / II-IV / 50.0 / 7 / 2 / 5 / 4 / 0.389 / IS / NA / CsA+MTX
Sociév
200118 / 100 / II-IV / 40.0 / 50 / 10 / 28 / 12 / 0.395 / IS / NA / CsA+MTX
-819T/C in donors with grade II-IV aGvHD
TT+TC / CC / TT+TC / CC / T
Xiao 201015 / 138 / II-IV / 43.5 / 67 / 11 / 43 / 17 / 0.384 / IU+IS / Asian / CsA+MTX
CsA+MMF
Xiao 201015 / 102 / II-IV / 23.5 / 80 / 8 / 17 / 7 / 0.397 / IS / Asian / CsA+MTX
CsA+MMF
Bertinetto 200616 / 77 / II-IV / 41.6 / 16 / 29 / 13 / 19 / 0.214 / IS / European / CsA+MTX
CsA+MMF
Azarpira 200817 / 18 / II-IV / 33.3 / 4 / 8 / 1 / 5 / 0.167 / IS / NA / CsA+MTX
Socié200118 / 100 / II-IV / 42.0 / 45 / 13 / 33 / 9 / 0.39 / IS / NA / CsA+MTX
-1082G/A in recipients with grade III-IV aGvHD
AA / AG / GG / AA / AG / GG / G
Sivula 200913 / 309 / III-IV / 9.3 / 76 / 146 / 53 / 10 / 9 / 10 / 0.454 / IS / NA / CsA+MTX
CsA+MMF
Tseng 200911 / 692 / III-IV / 37.0 / 128 / 213 / 95 / 72 / 125 / 59 / 0.466 / IU+IS / NA / CsA+MTX
Cavet 199919 / 124 / III-IV / 15.3 / 27 / 50 / 28 / 3 / 8 / 8 / 0.524 / IS / NA / CsA+MTX
Lin 200314 / 570 / III-IV / 18.4 / 157 / 219 / 89 / 26 / 51 / 28 / 0.442 / IS / NA / CsA+MTX
-1082G/A in recipients with grade II-IV aGvHD
AA / AG+GG / AA / AG+GG / G
Xiao 201015 / 138 / II-IV / 44.2 / 68 / 9 / 49 / 12 / 0.087 / IU+IS / Asian / CsA+MTX
CsA+MMF
Azarpira 200817 / 18 / II-IV / 50.0 / 1 / 8 / 1 / 8 / 0.444 / IS / NA / CsA+MTX
Bertinetto 200616 / 77 / II-IV / 41.6 / 10 / 35 / 13 / 19 / 0.435 / IS / European / CsA+MTX
CsA+MMF
Resende 201020 / 58 / II-IV / 34.5 / 16 / 22 / 6 / 14 / none / IS / Mixed / CsA+MTX
Socié 200118 / 100 / II-IV / 41.0 / 27 / 32 / 16 / 25 / 0.285 / IS / NA
-1082G/A in donors with grade III-IV aGvHD
AA / AG / GG / AA / AG / GG / G
Sivula 200913 / 309 / III-IV / 9.3 / 75 / 149 / 56 / 10 / 9 / 10 / 0.469 / IS / NA / CsA+MTX
CsA+MMF
Tseng 200911 / 901 / III-IV / 37.4 / 164 / 260 / 140 / 92 / 173 / 72 / 0.475 / IU+IS / NA / CsA+MTX
Cavet 199919 / 70 / III-IV / 11.4 / 21 / 25 / 16 / 3 / 4 / 1 / 0.45 / IS / NA / CsA+MTX
Lin 200314 / 570 / III-IV / 18.4 / 161 / 204 / 100 / 29 / 48 / 28 / 0.45 / IS / NA / CsA+MTX
-1082G/A in donors with grade II-IV aGvHD
AA / AG+GG / AA / AG+GG / G
Xiao 201015 / 138 / II-IV / 43.5 / 68 / 10 / 53 / 7 / 0.072 / IU+IS / Asian / CsA+MTX
CsA+MMF
Bertinetto 200616 / 77 / II-IV / 41.6 / 13 / 32 / 15 / 17 / 0.409 / IS / European / CsA+MTX
CsA+MMF
Azarpira 200817 / 18 / II-IV / 50.0 / 0 / 9 / 4 / 5 / 0.583 / IS / NA / CsA+MTX
Resende 201020 / 58 / II-IV / 34.5 / 1 / 37 / 1 / 19 / none / IS / Mixed / CsA+MTX
Socié200118 / 100 / II-IV / 40 / 24 / 34 / 15 / 25 / 0.305 / IS / NA / CsA+MTX
aGvHD:acute graft-versus-host disease, IU:HLA-identical unrelated ,IS:HLA-identical sibling ,MAF:minor allele frequencies, CsA:cyclosporine A,MTX: methotrexate, MMF: mycophenolatemofetil, NA:not recorded or available